The Latest Cardiac and Vascular News
EXCELLENT study demonstrates real-world benefits of CERENOVUS’ EMBOTRAP™ Revascularization Devices on clinical outcomes and first pass reperfusion IRVINE, Calif., Nov. 18, 2022 /PRNewswire/ — CERENOVUS, Inc., part of Johnson & Johnson MedTech*, today announced positive primary outcomes from the real-world EXCELLENT Registry focused on […]
Company Also Receives European CE Mark Approval for Novel Stroke Technology Designed for Difficult to Extract Blood Clots IRVINE, Calif., Dec. 10, 2018 — Johnson & Johnson Medical Devices Companies* today announced that its CERENOVUS business has launched the single […]
BRUSSELS–(BUSINESS WIRE)–CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received European CE mark approval for its BRAVO Flow Diverter. The device is approved for use in the treatment of patients suffering from intracranial aneurysms. […]
SAN FRANCISCO, July 24, 2018 /PRNewswire/ — CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced the first patients have been treated with its new EMBOTRAP II Revascularization Device since it became commercially available in the U.S. EMBOTRAP II is a next […]
IRVINE, Calif., May 21, 2018 /PRNewswire/ — CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EMBOTRAP II Revascularization Device, a next generation stent […]
ARISE II Clinical Trial Results Presented at International Stroke Conference LOS ANGELES – Jan. 25, 2018 – EMBOTRAP® Device, a device designed to remove clots from the brain following an ischemic stroke, demonstrated high success rates in restoring blood flow […]
IRVINE, CA – Jan. 24, 2018 – CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, today announced the launch of the GALAXY G3 MINI Coil, its smallest and softest embolic finishing coil, for use in the endovascular treatment […]
NICE, France, September 7, 2017 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the European Society of Minimally Invasive Neurological Therapy (ESMINT) 9th Annual Meeting. CERENOVUS, a name derived from the Latin words for ‘new’ […]
Johnson & Johnson rolls Pulsar Vascular, Neuravi into new Cerenovus neurovascular biz JULY 25, 2017 BY BRAD PERRIELLO – MassDevice Johnson & Johnson (NYSE:JNJ) said yesterday that it’s medical device division is rolling the Pulsar Vascular and Neuravi acquisitions into a new neurovascular business dubbed Cerenovus. The New […]
